Da Volterra attending ESMO Congress 2022 on Sept 9-13 in Paris, where key preclinical results showing the importance of DAV132 in immuno-oncology will be presented

Da Volterra attending ESMO Congress 2022 on Sept 9-13 in Paris, where key preclinical results showing the importance of DAV132 in immuno-oncology will be presented


Back to news page

Da Volterra attending ESMO Congress 2022 on Sept 9-13 in Paris, where key preclinical results showing the importance of DAV132 in immuno-oncology will be presented

The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. A great opportunity to interact with key-opinion leaders and debate on the most burning topics in oncology.

Dr. Meriem Messaoudene (CRCHUM, Montreal) will give a mini oral presentation of non-clinical results generated with DAV132 in immuno-oncology on Sunday Sept 11 at 15:25 CET in the Dijon Auditorium (Presentation Number: 1663MO): key data showing the crucial role of the gut microbiome on response to anti-PD-1 and the ability of DAV132 to maintain the full efficacy of anti-PD-1 by protecting the microbiome, will be presented!

DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: a proof-of-concept in tumor-bearing mice transplanted with human feces
M. Messaoudene (1), N. Saint-Lu (2), F. Sablier-Gallis (2), S. Ferreira (2), C. Le Bescop (2), M. Ponce1, C. Féger (3), A. Andremont (2), J. De Gunzburg (2), B. Routy (4)
(1) CRCHUM – Centre de recherche du CHUM, Montreal, CA, (2) Da Volterra, Paris, FR, (3) EMI Biotech, Grenoble, FR, (4) University of Montreal Research Center, Montreal, CA

Full event program available here